# Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma

> **NCT03189836** · PHASE1 · TERMINATED · sponsor: **Cogent Biosciences, Inc.** · enrollment: 26 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** ACTR707
- **BIOLOGICAL:** rituximab

## Key facts

- **NCT ID:** NCT03189836
- **Lead sponsor:** Cogent Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-10-04
- **Primary completion:** 2020-09-21
- **Final completion:** 2020-09-21
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2021-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03189836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03189836, "Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03189836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*